Psychedelics – News and Features

Phase 2 proof-of-concept study shows Esketamine could be an important treatment to bridge the gap that exists because of the delayed effect of most common antidepressants.

Outbreaks of lumpy skin disease (LSD) in the Balkan region fell dramatically by 95% from 7,483 in 2016 to 385 in 2017. The figures confirm that vaccination of cattle – recommended by EFSA in 2016 – is the most effective way to contain the disease.

By taking the process online, both existing and new researchers can submit their applications through a dedicated web portal, hopefully improving efficiency and security.

Scientists explain the links between music and drugs, that have existed for centuries.

Study of 61 patients found that almost 75 percent experienced an improvement in their migraine intensity after a three- to seven-day course of inpatient treatment with ketamine.

Researchers have determined the crystal structure of a specific dopamine receptor called D4 at an incredibly high resolution which is a major step towards designing improved psychiatric drugs with fewer side effects.

The 3-D atomic structure of an ion channel found in mammals that is implicated in a rare, inherited neurodegenerative disease in humans has been solved,

By employing mass spectrometry-based proteomics to analyze cerebral organoids, scientists identified the effects of psychedelic substances in the brain.

Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a 'reset' of their brain activity.

The ability to track the movements of single molecules has revealed how proteins on the surface of nerve cells control gates that turn chemical signals into electrical signals. The finding is a step forward in detailing mechanisms involved in neurological disease.